Nathalie Moreno - Bio-X Undergraduate Fellow
Home Department: Human Biology
Mentor: Alison Marsden (Pediatrics - Cardiology and Bioengineering)
Home Department: Human Biology
Mentor: Alison Marsden (Pediatrics - Cardiology and Bioengineering)
Home Department: undeclared
Mentor: Jenn Brophy (Bioengineering)
Dr. Nathan Lo is an Assistant Professor of Infectious Diseases. His research group studies the transmission of infectious diseases and impact of public health strategies with an ultimate goal of informing public health policy. His research blends diverse computational methodologies, including tools of epidemiology, modeling, pathogen genomics, and policy analysis. His interest spans across multiple infectious diseases including neglected tropical diseases, vaccine-preventable infections, and COVID-19.
Home Department: Mechanical Engineering
Faculty Advisor: Thomas Andriacchi
Talk Title: Changes In Tibiofemoral Kinematics And Kinetics During Stair Ascent After Partial Medial Meniscectomy
Event: American Society of Biomechanics 2008
Dr. Nathan Reticker-Flynn is a Biomedical Engineer and tumor immunologist working at the interfaces of cancer metastasis, tumor evolution, adaptive immunity, and immuno-oncology. His work employs mouse models and systems biology and genetic engineering to investigate interactions between tumors and the immune system during cancer metastasis. He performed his PhD work in Biomedical Engineering with Dr. Sangeeta Bhatia at MIT where he studied glycobiology and ECM interactions during cancer metastasis and his postdoctoral studies with Dr.
Dr. Nathanael Gray's Laboratory develops first-in-class chemical probes that are used to gain new biological insights into cellular processes that drive cancer and other diseases, and to pharmacologically validate potential clinically relevant targets. They take an integrative approach that combines medicinal chemistry, structural biology, biochemistry and molecular and cell biology to develop new therapeutic strategies. Their work has contributed to several approved and clinical stage drugs targeting BCR-ABL, Sphingosine-1-phosphate receptor (S1PR), EGFR, EML4-ALK and CDK7.